Ventrix specializes in the development of biotherapeutics that leverage the properties of extracellular matrix (ECM) to promote tissue repair and regeneration. ECM serves as a natural scaffold that not only provides structural support but also delivers biochemical signals essential for cell behavior, including proliferation and differentiation. The company recognizes the critical role of ECM in maintaining a healthy microenvironment for cells, as its composition and structure can vary significantly across different tissues. By harnessing the unique characteristics of ECM, Ventrix aims to create innovative therapies that facilitate the body’s natural healing processes.

The technologies developed by Ventrix focus on replicating the beneficial aspects of native ECM to enhance tissue repair mechanisms. Their approach is rooted in the understanding that functional ECM is vital for normal cellular activities, and without it, the repair processes can be severely hindered. By creating a new class of biotherapeutics, Ventrix seeks to provide solutions that not only support the structural integrity of tissues but also promote the regeneration of healthy tissue environments, ultimately improving patient outcomes in various therapeutic applications.

United States

Ventrix provides solutions for the heart. Ventrix, Inc. is a privately held company and has established a firm foothold in San Diego, CA. In 2012, Ventrix closed a Series A financing round and has received funding from NIH and NSF SBIR awards.

Ventrix is focused on delivering a biomaterial scaffold for cardiac repair for heart attack patients who currently have very limited treatment options. Ventrix is interested in partnership opportunities with leading Healthcare Technology companies. If you are interested in a partnership or investment opportunity with Ventrix, please contact us.

Ventrix

Company Details